Advanced Proteome Therapeutics Corp.

Recent News

  • Advanced Proteome Therapeutics Announces Its Proposed Plan of Arrangement

    Burnaby, British Columbia--(Newsfile Corp. - January 17, 2023) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the Supreme Court of British Columbia (the "Court") has issued an interim order (the "Interim Order") on January 16, 2023 in connection with the Company's proposed Plan of Arrangement (see below). The Interim Order, among other things, authorizes the holding of an annual and special meeting (the "Meeting") of the holders of common shares...

    2023-01-17 2:39 PM EST
  • Advanced Proteome Therapeutics Announces Closing of Non-Brokered Private Placement

    Burnaby, British Columbia--(Newsfile Corp. - December 23, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that, subject to the approval of the TSX Venture Exchange, it has closed a non-brokered private placement (the "Private Placement" or the "Offering") raising gross proceeds of $72,500.00 by the issuance of 1,450,000 shares at a price of $0.05 per share.There were no finders' fees paid in connection with the Private Placement. The shares issued under the...

    2022-12-23 5:08 PM EST
  • Advanced Proteome Therapeutics Announces Appointment of Mr. Cory Brandolini to the Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - November 21, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that it has appointed Mr. Cory Brandolini to the board of directors.Mr. Brandolini has over 3 decades of experience in the capital markets and as an advisor to disruptive, high growth software companies across many verticals in the technology sector. Over the course of his career, he has helped raise hundreds of millions of...

    2022-11-21 7:40 PM EST
  • Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry

    Vancouver, British Columbia--(Newsfile Corp. - August 17, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has had its technology featured in a peer-reviewed publication.The manuscript entitled, "Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates" by Sarrett, et al. has been published in the prestigious journal, Bioconjugate Chemistry. Bioconjugate Chemistry is a peer-reviewed journal focused on bioconjugation and published by the American...

    2022-08-17 8:30 AM EDT
  • Advanced Proteome Therapeutics Receives Issued Patent

    Vancouver, British Columbia--(Newsfile Corp. - August 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the United States Patent and Trademark Office has issued a patent to its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").On August 2, 2022, APTI was issued U.S. Patent No. 11,400,165 titled 'Composition and method for modifying polypeptides'. The patent covers highly site-selective antibody conjugate compositions produced with APTI's two-step conjugation technology including the half-product of the first...

    2022-08-03 1:45 PM EDT
  • Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims

    Vancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has received a notice of allowance for patent claims covering key intellectual property.APTI has been informed that the first set of claims from US patent application 16/180,960 have been allowed. These claims cover highly site-selective antibody conjugate compositions produced with APTI's two step conjugation technology...

    2022-04-13 10:28 AM EDT
  • Advanced Proteome Therapeutics Announces Warrant Extension

    Vancouver, British Columbia--(Newsfile Corp. - March 18, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") announces that, it has applied to the TSX Venture Exchange for approval to amend the expiration of certain outstanding warrants (the "Warrants"). The Warrants' exercise price and original expiry date are detailed below. The Warrants expiry date is to be extended to September 30, 2022. The warrants to be amended do not include any warrants issued to finders or...

    2022-03-18 3:46 PM EDT
  • Advanced Proteome Therapeutics Update on Plans for 2022

    Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is providing an update on plans for the upcoming year.APTI is pleased to report that, after operational advancements and continued antibody-drug conjugate (ADC) platform development and validation in 2021, 2022 is expected to be a transformational year. In July of 2021, Dr. Benjamin Krantz was appointed CEO of...

    2022-02-03 2:50 PM EST